Claims statistics relating to Donanemab and Lecanemab

Written by Claude Haiku 5.5 from the extracted text on 21 Oct 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

This FOI release from the Department of Veterans' Affairs (reference LEX 84923, decision dated 15 September 2026) is a short statistical response to a request for data on current and former Australian Defence Force members using the Department of Veterans' Affairs Veteran Card to access Donanemab or Lecanemab. For 1 January 2025 to 2 September 2026, the department reports four clients, 20 prescriptions, all male and aged 65 to 83, with two in Victoria and two in Queensland. The total cost of DVA-funded subsidy is $66,181.86. The release notes that the common use of these medications is for the treatment of Alzheimer's disease. The document is a data response only, with no policy documents, briefings or exemptions identified in the extract provided.